These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35590003)

  • 21. Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site.
    Sõrmus T; Lavogina D; Teearu A; Enkvist E; Uri A; Viht K
    J Med Chem; 2022 Aug; 65(16):10975-10991. PubMed ID: 35960538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
    Kwarcinski FE; Fox CC; Steffey ME; Soellner MB
    ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
    Lu X; Smaill JB; Patterson AV; Ding K
    J Med Chem; 2022 Jan; 65(1):58-83. PubMed ID: 34962782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
    Forster M; Gehringer M; Laufer SA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
    Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer.
    Zhang B; Zhu C; Chan ASC; Lu G
    Eur J Med Chem; 2023 Aug; 256():115457. PubMed ID: 37207533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.
    Das D; Hong J
    Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.
    Chen P; Tang G; Zhu C; Sun J; Wang X; Xiang M; Huang H; Wang W; Li L; Zhang ZM; Gao L; Yao SQ
    J Am Chem Soc; 2023 Feb; ():. PubMed ID: 36774655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification.
    Browne CM; Jiang B; Ficarro SB; Doctor ZM; Johnson JL; Card JD; Sivakumaren SC; Alexander WM; Yaron TM; Murphy CJ; Kwiatkowski NP; Zhang T; Cantley LC; Gray NS; Marto JA
    J Am Chem Soc; 2019 Jan; 141(1):191-203. PubMed ID: 30518210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors.
    Reinecke M; Brear P; Vornholz L; Berger BT; Seefried F; Wilhelm S; Samaras P; Gyenis L; Litchfield DW; Médard G; Müller S; Ruland J; Hyvönen M; Wilhelm M; Kuster B
    Nat Chem Biol; 2024 May; 20(5):577-585. PubMed ID: 37904048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
    Hu C; Dong X
    Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
    Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irreversible protein kinase inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covalent inhibitors: back on track?
    Gehringer M
    Future Med Chem; 2020 Aug; 12(15):1363-1368. PubMed ID: 32597212
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
    Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
    Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible covalent inhibition of a protein target.
    Lee CU; Grossmann TN
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8699-700. PubMed ID: 22806944
    [No Abstract]   [Full Text] [Related]  

  • 39. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
    Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
    J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.
    Lemeer S; Zörgiebel C; Ruprecht B; Kohl K; Kuster B
    J Proteome Res; 2013 Apr; 12(4):1723-31. PubMed ID: 23495751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.